Overview and Scope
Hypertrophic cardiomyopathy (HCM) refers to a disorder of the heart when the left ventricle, the major pumping chamber, is affected by the thickening of the heart muscle. This is most prevalent at the septum. The septum is the muscular wall that separates the heart's left and right sides. The treatment strategy for hypertrophic cardiomyopathy is tailored to the individual and specific recommendations may differ.
Sizing and Forecast
The hypertrophic cardiomyopathy treatment market size has grown steadily in recent years. It will grow from $1.31 billion in 2024 to $1.37 billion in 2024 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to advances in diagnostic technologies, drug therapies, surgical interventions, clinical guidelines.
The hypertrophic cardiomyopathy treatment market size is expected to see steady growth in the next few years. It will grow to $1.62 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, personalized medicine, regenerative medicine. Major trends in the forecast period include early intervention, patient-centered care, wearable health technology, health equity initiatives.
To access more details regarding this report, visit the link:
Segmentation & Regional Insights
The hypertrophic cardiomyopathy treatment market covered in this report is segmented –
1) By Disease Type: Obstructive Hypertrophic Cardiomyopathy Treatment; Non-Obstructive Hypertrophic Cardiomyopathy Treatment
2) By Diagnosis: Chest X-Ray; Echocardiogram; Electrocardiogram (ECG); Treadmill Stress Test; Cardiac Catheterization; Cardiac MRI; Cardiac CT Scan; Blood Tests; Genetic Testing Or Screening
3) By Treatment: Medication; Surgically Implanted Devices; Nonsurgical Procedures; Surgery
4) By End-User: Hospitals; Research Institutes; Specialty Clinics
North America was the largest region in the hypertrophic cardiomyopathy treatment market in 2024. The regions covered in hypertrophic cardiomyopathy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13017&type=smp
Major Driver Impacting Market Growth
The increase in obesity is expected to propel the growth of the hypertrophic cardiomyopathy treatment market going forward. Obesity describes an abnormal or excessive fat build up that harms health. Obesity frequently arises from consuming more calories than are burnt through exercise and daily activities. The phenotype of hypertrophic cardiomyopathy (HCM) is thought to be influenced by obesity, which is very frequent in people with HCM. For instance, in March 2022, according to a report published by the World Health Organization, a Switzerland-based organization for public health, obesity affects more than one billion people globally, including 650 million adults, 340 million adolescents and 39 million children. Further, by 2025, roughly 167 million additional individuals will be less healthy due to being overweight or obese. Therefore, the increase in obesity will drive the hypertrophic cardiomyopathy treatment market.
Key Industry Players
Major players in the hypertrophic cardiomyopathy treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Mylan N.V., Sun Pharmaceutical Industries Ltd., PerkinElmer Inc., Cipla Ltd., Aurobindo Pharma Ltd., Bio-Rad Laboratories Inc., Covance Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo International Inc., Lupin Limited, Zydus Lifesciences Limited, XyloCor Therapeutics Inc., Cytokinetics Inc., Santhera Pharmaceuticals Holding AG, DiNAQOR AG, Correvio Pharma Corp, Cardurion Pharmaceuticals Inc.
The hypertrophic cardiomyopathy treatment market report table of contents includes:
1. Executive Summary
2. Hypertrophic Cardiomyopathy Treatment Market Characteristics
3. Hypertrophic Cardiomyopathy Treatment Market Trends And Strategies
4. Hypertrophic Cardiomyopathy Treatment Market - Macro Economic Scenario
5. Global Hypertrophic Cardiomyopathy Treatment Market Size and Growth
.....
32. Global Hypertrophic Cardiomyopathy Treatment Market Competitive Benchmarking
33. Global Hypertrophic Cardiomyopathy Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Hypertrophic Cardiomyopathy Treatment Market
35. Hypertrophic Cardiomyopathy Treatment Market Future Outlook and Potential Analysis
36. Appendix
Explore the trending research reports from TBRC:
https://goodprnews.com/wayside-control-market-analysis/
https://goodprnews.com/nachos-market-report/
https://goodprnews.com/fentanyl-market-share/
https://goodprnews.com/wayside-control-market-analysis/
https://goodprnews.com/nachos-market-report/
https://goodprnews.com/fentanyl-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
What is Hypertrophic cardiomyopathy Market Companies Report?The Hypertrophic Cardiomyopathy (HCM) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted HCM symptoms market size from 2018 to 2030 segmented by seven major markets.
The report also covers current Hypertrophic Cardiomyopathy (HCM) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the marketWhat is Hypertrophic Cardiomyopathy Market Drugs Chapters?The drug chapter segment of the Hypertrophic Cardiomyopathy (HCM) report encloses the detailed analysis of HCM marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
It also helps understand the Hypertrophic Cardiomyopathy (HCM) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.Management of Hypertrophic Cardiomyopathy (HCM) requires a multi-disciplinary approach that includes neonatologists, cardiologists, surgeons, nutritionists, pharmacists, nurses, and social workers.
Guidelines have been set forth regarding the optimal HCM classification and management, but they must be taken in the situation and cannot be used in every circumstance.
The primary approach is pharmacologic support, and if the patient is refractory to medication, non-pharmacologic support may be considered.What are the Hypertrophic Cardiomyopathy (HCM) Emerging Drugs?Mavacamten is an investigational, novel, oral, allosteric modulator of cardiac myosin; mavacamten reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation, resulting in hypercontractility, left ventricular hypertrophy, and reduced compliance.Mavacamten is initially being developed for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
Based on its mechanism of action and evidence of therapeutic activity, mavacamten is also being studied in the clinic to treat symptomatic non-obstructive HCM and among a targeted population of patients with heart failure with preserved ejection fraction (HFpEF).What is Hypertrophic Cardiomyopathy Market Share Outlook?The Hypertrophic Cardiomyopathy (HCM) market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Hypertrophic Cardiomyopathy (HCM) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.This segment gives a thorough detail of Hypertrophic Cardiomyopathy (HCM) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Medical procedure, an embedded gadget, or medication to diminish or manage the pulse might be utilized to hypertrophic cardiomyopathy (HCM) therapeutics.
HCM is an inherited condition that makes the heart muscle thicken strangely.
Despite the fact that there is no solution for HCM as of now, existing medicines can assist with controlling side effects and forestall results.
Be that as it may, the hypertrophic cardiomyopathy (HCM) therapeutics is reliant upon how the heart is influenced and what indications an individual has.
Most of individuals have no manifestations or extreme issues.The absolute most normal manifestations of HCM incorporate chest torment, windedness, and unpredictable heart rhythms (arrhythmias).
Because of hypertrophic cardiomyopathy, different extra issues, including arrhythmias or unpredictable cardiovascular rhythms, heart square, and endocarditis, may create in certain people.
